C.H. Barrios

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Fátima Cardoso, Shani Paluch–Shimon, Elżbieta Senkus et al. · Annals of Oncology · 2020 · 1.4K citations · Full text

Medicine, Oncology, Surgery +13

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

Fátima Cardoso, Elżbieta Senkus, A. Costa et al. · Annals of Oncology · 2018 · 1.2K citations · Full text

Medicine, Oncology, Breast Oncology +16

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

David R. Spigel, Filippo de Marinis, Giuseppe Giaccone et al. · Annals of Oncology · 2019 · 144 citations

Medicine, Oncology, Pharmacology +11

Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

H. S. Rugo, Sherene Loi, Sylvia Adams et al. · Annals of Oncology · 2019 · 115 citations · Full text

Medicine, Oncology, Breast Oncology +13

LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

D.W. Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2020 · 97 citations

Medicine, Oncology, Pharmacology +16